The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes, marking the first once-weekly basal insulin approved in the US.
|Poll|March 24, 2016
A 47-year-old Man with Peripheral Edema
Author(s)ReelDx
VIDEO: Note marked tumescence in patient’s hands, pitting edema in lower extremities. Does PMH contribute? Dx?
Advertisement
A 47-year-old man presents c/o swelling in extremities-hands x1 week; legs, x1 month. Marked tumescence is seen in the hands and pitting edema is noted on lower legs. PMH: HTN, T2DM, hyperlipidemia; S/P cholecystectomy. Meds: HCTZ; lisinopril; amlodipine; insulin. See differential diagnosis below.
What do you suspect as the diagnosis?
Advertisement
Related to this article
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
5